Skip to main content

Table 2 Hazard ratio of 1% increase in GA and HbA1c levels for each endpoint

From: Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

 

GA

HbA1c

Cause of death

 

Hazard ratio (95% CI)

p value

Hazard ratio (95% CI)

p value

All-causes

Model 1

1.00 (0.97–1.03)

0.815

0.87 (0.74–1.02)

0.088

Model 2

1.01 (0.98–1.05)

0.517

0.92 (0.77–1.11)

0.392

Model 3

1.03 (1.01–1.06)

0.017

1.01 (0.87–1.17)

0.888

Model 1

1.08 (1.01–1.15)

0.016

1.12 (0.80–1.58)

0.518

ASCVD

Model 2

1.09 (1.02–1.17)

0.013

1.14 (0.78–1.66)

0.501

Model 3

1.10 (1.05–1.16)

< 0.001

1.35 (1.02–1.77)

0.033

Model 1

0.99 (0.95–1.02)

0.477

0.82 (0.68–0.99)

0.034

Non-ASCVD

Model 2

0.99 (0.96–1.03)

0.686

0.88 (0.71–1.08)

0.206

Model 3

1.01 (0.98–1.05)

0.409

0.93 (0.78–1.10)

0.374

  1. Model 1, in which the hazard ratios were estimated using baseline GA or HbA1c values; model 2, which used mean values of GA or HbA1c during the follow-up period; and model 3, in which GA or HbA1c values during the follow-up period were treated as time-dependent variables
  2. ASCVD atherosclerotic cardiovascular disease, GA glycated albumin, HbA1c hemoglobin A1c
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us